Welcome to our dedicated page for Profound Med news (Ticker: PROF), a resource for investors and traders seeking the latest updates and insights on Profound Med stock.
Profound Medical Corp. develops and markets interventional MRI medical devices for incision-free tissue ablation. Its recurring news centers on TULSA-PRO® and the TULSA Procedure™, which use real-time MRI guidance, robotically controlled transurethral ultrasound and temperature feedback to ablate prostate tissue in prostate cancer and benign prostatic hyperplasia.
Company updates also cover Sonalleve®, an MRI-guided therapy used for pain palliation of bone metastases, desmoid tumors and osteoid osteoma, as well as gynecologic conditions including uterine fibroids and adenomyosis. Recurring developments include financial results, revenue guidance, payer coverage, CAPTAIN post-market clinical data, scientific-meeting presentations, treatment-site adoption milestones and investor conference updates.
Profound Medical (NASDAQ:PROF) announced the introduction of its latest Treatment Delivery Consol (TDC) software for the TULSA-PRO® platform, which is being deployed across the existing installed base. The upgrade builds on prior TULSA-AI® modules to enhance procedural efficiency, physician experience, and reduce planning complexity.
The new software adds real-time interventional MRI control, giving surgeons greater direct control over TULSA-PRO’s supervised robotic autonomy, along with physician-requested user interface and hardware-control improvements. According to Profound Medical, these features are intended to streamline TULSA Procedure™ workflows and provide a potential roadmap to enable surgeons to perform up to six procedures per system per day.
Profound Medical (NASDAQ:PROF; TSX:PRN) announced a management change, promoting Matthew Sobczyk from Corporate Controller to Interim Chief Financial Officer, effective immediately. Sobczyk, who joined Profound in 2020, succeeds Rashed Dewan, who has stepped down as CFO.
According to Profound Medical, Dewan will remain on a short-term consulting contract to support a smooth transition. CEO and Chairman Arun Menawat said Sobczyk’s deep knowledge of the company and financial expertise are expected to help maintain continuity and operational discipline as Profound advances adoption of its MRI-guided TULSA-PRO and Sonalleve technologies.
Profound Medical (NASDAQ:PROF) announced the launch of Let’s Huddle, a global patient community aimed at supporting men and their families throughout the prostate care journey. Led by Global Patient Ambassador Leonard Wheeler, a former NFL player and prostate cancer survivor, the initiative focuses on education, peer connection, and advocacy around prostate disease.
Let’s Huddle brings together patients, survivors, care partners, healthcare professionals, and advocates to share real patient experiences, educational resources, and survivorship support. According to Profound, the program extends its commitment beyond its MRI-guided TULSA-PRO platform by helping organizations strengthen patient education, build trust, and promote comprehensive, patient-centered prostate care worldwide.
Profound Medical (NASDAQ:PROF) reported Q2‑2026 revenue of $2.5 million, up 12% year-over-year, with $1.6 million from recurring non-capital sales and $871,000 from capital equipment. About $3.1 million of TULSA shipments slipped into July, which the company said reflected logistics timing only; excluding this, revenue would have been about $5.6 million, or 153% growth.
Gross margin rose to 78% from 73%, while operating expenses fell 16% to roughly $13.0 million, improving net loss 39% to $9.5 million ($0.26 per share). Cash was $38.3 million at June 30, 2026. The TULSA-PRO installed base reached 84, payer coverage grew by approximately 18.3 million lives, and two employer health plans added the TULSA Procedure™ as a covered service. Profound reiterated its 2026 revenue outlook of about $25.0 million, implying 56% growth, and continues to expect full-year gross margin of at least 70%.
Profound Medical (NASDAQ:PROF; TSX:PRN) reported new Level 1 post-market data from the randomized CAPTAIN trial comparing the TULSA Procedure™ with robotic radical prostatectomy in men with organ-confined, intermediate-risk Gleason 7 prostate cancer.
At 1 month, there was no median change in penile length after whole-gland TULSA, versus a median 0.65 cm reduction after robotic RP. According to Profound, a mixed-effects model showed a 0.42 cm between-arm difference (p<0.001), favoring TULSA. The company positions these results as additional quality-of-life context to previously disclosed CAPTAIN primary safety data, where TULSA demonstrated statistically significant superiority over robotic RP in preserving erectile function and urinary continence at 6 months.
CAPTAIN is a prospective, multi-center randomized trial that ultimately treated 211 patients across 23 sites. Its primary endpoints assess preservation of erectile potency and urinary continence at 1 year and cancer control outcomes at 3 years.
Profound Medical (NASDAQ:PROF; TSX:PRN) will release its second quarter 2026 financial results after market close on Thursday, August 6, 2026. Management will host a conference call at 4:30 p.m. ET the same day to review results and discuss business developments.
Investors can register for the live call via the provided online registration link, and the conference will also be broadcast live and subsequently archived in the Investors section of the company’s website.
Profound Medical (NASDAQ:PROF) announced that its MRI-guided, AI-powered, robotically driven and incisionless TULSA Procedure will feature prominently at the Society of Robotic Surgery Annual Meeting in Fort Lauderdale, FL, on July 23-26, 2026, in multiple physician-led clinical presentations and a lunch symposium.
The company will also be one of only eight firms spotlighted in the new Society of Incisionless Surgery plenary session, highlighting robotic autonomy and image-guided, energy-based treatment. In addition, Profound’s management will join an SRS2026 Investor Session on July 22, 2026, to discuss innovative robotic technologies and TULSA-PRO.
Profound Medical (NASDAQ:PROF) will showcase TULSA-PRO, the TULSA Procedure and iMRI prostate ablation at AUA2026 in Washington, DC. Four oral presentations will cover MRI-guided transurethral ultrasound ablation outcomes, safety and real‑world data in localized prostate cancer.
The company will demonstrate TULSA-PRO and a Siemens MAGNETOM Free.Max MR at Booth #413 and is launching an initiative to explore integrating PSMA PET molecular imaging into TULSA-PRO treatment planning to support intent-to-treat decisions and patient monitoring.
Profound Medical (NASDAQ: PROF) reported voting results from its May 13, 2026 Annual General and Special Meeting. Shareholders representing 25,347,133 shares, or 69.754% of outstanding shares, were present. All matters in the April 2, 2026 circular were approved, including eight director elections, auditor appointment, and long-term incentive plan resolutions.
Profound Medical (NASDAQ:PROF) reported Q1 2026 revenue of approximately $5.3M, up 104% YoY, with recurring non-capital revenue of $2.5M and capital equipment revenue of $2.9M. Gross margin was 72%, operating expenses were $11.8M, and net loss narrowed to $7.0M ($0.19/share).
The company ended Q1 with $50.3M cash, a TULSA-PRO installed base of 80 systems, shipment of six systems, and announced Humana coverage adding ~6.9M covered lives; full-year 2026 revenue guidance is ~$25M.